Managing Weight Regain and Health Risks After Stopping GLP-1 Agonists

GLP-1 Receptor Agonists (GLP-1 RAs) like semaglutide and tirzepatide have revolutionized the treatment of obesity and type 2 diabetes, leading to significant weight loss and improved cardiometabolic markers. However, upon discontinuation, patients often experience substantial weight regain and a reversal of these beneficial effects. This review addresses the critical need for a comprehensive understanding of clinical management strategies for weight regain and associated cardiometabolic consequences after stopping GLP-1 RAs.

The reviewed literature consistently indicates that discontinuing GLP-1 RA therapy leads to significant weight regain, often reversing the majority of initial weight loss. Studies show that patients typically regain 60-70% of their lost weight within 12 months of stopping treatment. This weight regain is frequently accompanied by a deterioration of cardiometabolic parameters, including increases in HbA1c (a measure of blood sugar control), blood pressure, and lipid levels. The reversal of these benefits underscores the chronic nature of obesity and the need for sustained intervention. > The most critical finding is that the majority of weight loss achieved with GLP-1 RAs is lost within one year of discontinuation, with two-thirds of patients experiencing a return to baseline or near-baseline weight, highlighting the need for long-term management strategies.